Different capabilities of monocytes from patients with systemic lupus erythematosus and rheumatoid arthritis to induce glycosylation alterations of acute phase proteins in vitro.
Open Access
- 1 January 1992
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 51 (1) , 67-72
- https://doi.org/10.1136/ard.51.1.67
Abstract
The effect of conditioned medium on the biosynthesis and glycosylation profile of acute phase proteins secreted by the human hepatoma cell line Hep G2 was studied. Conditioned medium was prepared from nonactivated [CM-LPS(-)] and ex vivo lipopolysaccharide activated [CM-LPS(+)] monocytes from eight patients with active rheumatoid arthritis (RA), five patients with active systemic lupus erythematosus (SLE), and seven healthy subjects. The biosynthesis of albumin, alpha 1-antichymotrypsin and alpha 1-proteinase inhibitor and the profile of glycosylation of proteinase inhibitor were analysed. CM-LPS(-) from patients with SLE had a similar effect to CM-LPS(-) from healthy subjects. In contrast, CM-LPS(-) from patients with RA had the same effect as CM-LPS(+) from healthy donors. A similar effect to that of CM-LPS(+) of healthy subjects was seen with CM-LPS(+) from patients with SLE and with CM-LPS(+) from patients with RA. The treatment of CM-LPS(+) with antibodies against interleukin 6 neutralised most of its ability to induce changes in the biosynthesis and glycosylation of acute phase proteins. Antibodies to interleukin 1 and tumour necrosis factor alpha had only a limited effect on the ability of CM-LPS(+) to induce changes of albumin and alpha 1-antichymotrypsin syntheses, whereas they had no effect on the biosynthesis and glycosylation of proteinase inhibitor. These results indicate that: (a) monocytes isolated from patients with active SLE and active RA have different capabilities of inducing alterations of acute phase proteins in vitro; (b) ex vivo activation of monocytes from patients with SLE leads to the full induction of its capabilities to change acute phase proteins, whereas the activation of monocytes from patients with RA has no additive effects; and (c) interleukin 6 seems to be a major cytokine involved in the regulation of the glycosylation pattern of acute phase proteins.Keywords
This publication has 38 references indexed in Scilit:
- Inflammatory and immunomodulatory roles of TGF-βImmunology Today, 1989
- Human Monoclonal Antibody Technology—Are its Achievements, Challenges, and Potential Appreciated?Scandinavian Journal of Immunology, 1989
- Affinity electrophoresis for studies of mechanisms regulating glycosylation of plasma proteinsElectrophoresis, 1989
- Affinity electrophoresis for diagnosis fo cancer and inflammatory conditionsElectrophoresis, 1989
- Interleukin‐6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritidesArthritis & Rheumatism, 1988
- Production of Tumour Necrosis Factor-a, Interferon-y and lnterleukin-2 by Peripheral Blood Mononuclear Cells of Subjects Suffering from Rheumatoid ArthritisScandinavian Journal of Rheumatology, 1988
- Microheterogeneity of alpha1‐acid glycoprotein in the detection of intercurrent infection in systemic lupus erythematosusArthritis & Rheumatism, 1987
- Defective monocyte function in patients with systemic lupus erythematosusClinical Immunology and Immunopathology, 1985
- Interleukin-1Clinical Infectious Diseases, 1984
- The 1982 revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1982